MARKET

SYNH

SYNH

SYNEOS HEALTH
NASDAQ

Real-time Quotes | Nasdaq Last Sale

75.50
-0.83
-1.09%
Closed 16:11 03/02 EST
OPEN
76.32
PREV CLOSE
76.33
HIGH
77.50
LOW
74.72
VOLUME
3.10M
TURNOVER
--
52 WEEK HIGH
81.35
52 WEEK LOW
30.02
MARKET CAP
7.88B
P/E (TTM)
41.32
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Syneos Health enters 7M secondary offering
Syneos Health ([[SYNH]] -4.1%) announces that it has commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners and Advent International of an aggregate of 7M shares.The selling
Seekingalpha · 1d ago
Syneos Health Offering Prices at Discount; Syneos to Buy Additional 600,000 Shares From Sellers
MT Newswires · 1d ago
Syneos Health Announces Pricing of Secondary Offering of Common Stock
MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Cont...
GlobeNewswire · 1d ago
BRIEF-Syneos Health Announces Secondary Offering Of Common Stock
reuters.com · 1d ago
BRIEF-Syneos Health And Protocol First Partner To Accelerate Collection And Review Of Clinical Trial Data
reuters.com · 6d ago
Syneos Health Says Partners With Protocol First To Accelerate Collection, Review Of Clinical Trial Data
Syneos Health and Protocol First Partner to Accelerate Collection and Review of Clinical Trial Data MORRISVILLE, N.C. and SALT LAKE CITY, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), the only
Benzinga · 6d ago
Syneos Health, Protocol First to Accelerate Collection, Review of Clinical Trial Research Data
MT Newswires · 6d ago
Syneos Health Communications Bolsters Value, Access and Public Affairs Offerings with Key Senior Hires
Syneos Health Communications - the portfolio of Syneos Health agencies designed to deliver insights-driven integrated communications spanning advertising, public relations, patient advocacy, medical communications, managed markets, omnichannel, digital, na...
GlobeNewswire · 02/23 14:51
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYNH. Analyze the recent business situations of SYNEOS HEALTH through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYNH stock price target is 85.60 with a high estimate of 91.00 and a low estimate of 80.00.
EPS
Institutional Holdings
Institutions: 478
Institutional Holdings: 135.47M
% Owned: 129.87%
Shares Outstanding: 104.31M
TypeInstitutionsShares
Increased
141
9.69M
New
92
2.49M
Decreased
79
10.69M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/Independent Director
John Dineen
Chief Executive Officer/Director
Alistair Macdonald
Chief Financial Officer
Jason Meggs
Corporate Executive
Paul Colvin
Corporate Executive
Michelle Keefe
Chief Human Resource Officer
Lisa van Capelle
Director
Tom Allen
Executive Vice President/Chief Accounting Officer
Robert Parks
Senior Vice President - Finance/Chief Accounting Officer
Donna Kralowetz
General Counsel/Secretary
Jonathan Olefson
Independent Director
Todd Abbrecht
Independent Director
Thomas Allen
Independent Director
Bernadette Connaughton
Independent Director
Linda Harty
Independent Director
William Klitgaard
Independent Director
John Maldonado
Independent Director
Kenneth Meyers
Independent Director
Matthew Monaghan
Independent Director
Joshua Nelson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About SYNH
Syneos Health Inc. is a fully integrated biopharmaceutical solutions providing company. The Company offers both stand-alone and integrated biopharmaceutical product development solutions through its Contract Research Organization (CRO) and Contract Commercial Organization (CCO), ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products. It brings together approximately 24,000 clinical and commercial professionals with the ability to support customers in more than 110 countries. Together it shares insights, leverages latest technologies and apply advanced business practices to deliver important therapies to patients.

Webull offers kinds of Syneos Health Inc stock information, including NASDAQ:SYNH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYNH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYNH stock methods without spending real money on the virtual paper trading platform.